Liver carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
Totally, 427 upregulated (e.g., cell division cycle associated 5 [<i>CDCA5</i>], kinesin family member 4A [<i>KIF4A</i>], TPX2 microtubule nucleation factor [<i>TPX2</i>]) and 313 downregulated (e.g., metallothionein 1E [<i>MT1E</i>]) DEGs were identified in HCC.
|
31593490 |
2019 |
Liver carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
Targeting DTL induces cell cycle arrest and senescence and suppresses cell growth and colony formation through TPX2 inhibition in human hepatocellular carcinoma cells.
|
29606879 |
2018 |
Liver carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
Subgroup analysis revealed that increased TPX2 expression was related to worse prognosis of gastric cancer and hepatocellular cancer, while irrelevant to esophageal squamous cell cancer at 5-year survival rate.
|
30412141 |
2018 |
Liver carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
In this study, increased TPX2 protein expression was present in 16 (42%) of 38 primary HCCs and was associated with advanced stage, distant metastatic HCCs and poor prognosis.
|
28638452 |
2017 |
Liver carcinoma
|
0.360 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
Liver carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
We finally extracted four genes, AKR1B10, HCAP-G, RRM2, and TPX2, as candidate therapeutic targets for HCC. siRNA-mediated knockdown of these candidate genes inhibited the proliferation of HCC cells and the growth of HCC xenografts transplanted into immunodeficient mice.
|
20388846 |
2010 |
Liver carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
Two other Ags (HCA519 and HCA90) were highly overexpressed in HCC and also expressed in cancer cell lines of lung, prostate, and pancreas, but not in the respective normal tissues.
|
12097419 |
2002 |
Colorectal Carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
Additionally, combined high expression of MYC, AURKA and TPX2 proved to be a poor prognostic indicator of colorectal cancer patient survival.
|
25632068 |
2015 |
Colorectal Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
After the generation of a profile of genes overexpressed in primary colorectal cancer (CRC) we selected 5 genes, Ese-3b, Fls353, PBEF, SPARC and Smad5 for a more detailed analysis using phage display-derived antibodies.
|
12209988 |
2002 |
Colorectal Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Twelve genes, including Smad5 and Fls353, have previously been shown to be overexpressed in CRC.
|
10601642 |
1999 |
Colorectal Carcinoma
|
0.330 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Elevated TPX2 expression was significantly associated with poor DFS (pooled hazard ratio [HR] =2.48, 95% confidence interval [CI]: 1.96-3.13) and OS (pooled HR =2.66, 95% CI: 2.04-3.48) of digestive system malignancies.
|
29551902 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overexpression of targeting protein for Xklp2 (TPX2) has been identified in numerous malignant tumors.
|
29620263 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
EC: Endometrial cancer; 3'-UTR: 3'-untranslated regions; TPX2: target protein for Xenopus kinesin-like protein 2; TCGA: the Cancer Genome Atlas; UCEC: uterine corpus endometrial carcinoma; CCK-8: cell counting kit-8; OD: optical density; FCM: flow cytometry; EMT: epithelial-mesenchymal transition.
|
29888640 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Xenograft tumor in nude mice was used to determine the effect of TPX2 in OC cells in vitro.
|
29904936 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, we validated p100 as a direct target of miR-320a, a tumor suppressing microRNA repressing lung cancer cell migration.
|
29159900 |
2018 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Finally, we disclosed that the concurrent overexpression of WDR62 and TPX2 is common in diverse human cancers, using data from the Cancer Genome Atlas.
|
28277612 |
2017 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, we consider the targeting TPX2 could provide novel therapeutic strategies for cancer.
|
28638452 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RNAi was used for TPX2 protein expression knockdown, and a clonogenic assay, immunostaining, double thymidine block, image-cytometry analysis, and tumor spheroid assay were used to analyze the role of TPX2 in tumor cell growth, cell cycle progression, multinuclearity, ploidy, and tumorigenicity, respectively; finally, Western blotting was used to analyze anticancer mechanisms in TPX2 targeting.
|
28761362 |
2017 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The targeting protein for Xklp2 (TPX2) is a microtubule- and, cell cycle-associated protein who's overexpression has been reported in various malignancies.
|
25914189 |
2015 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Partial degradation of the p100 subunit to generate p52 subunit is a hallmark of the alternative NF-κB pathway, which has been implicated in cancer.
|
26112410 |
2015 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, we demonstrated that CD34-positive microvessels were significantly reduced in tumors treated with TPX2 siRNA compared to tumors that treated with Control siRNA.
|
25914189 |
2015 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overexpressed in cancers, TPX2 is being established as marker for the diagnosis and prognosis of malignancies.
|
24556998 |
2014 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The abnormal expression of TPX2 in a variety of malignant tumor types has been reported, however less is known about its role in cervical cancer.
|
24718984 |
2014 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Abnormal expression of TPX2 in various types of malignant tumors has been reported, but less is known for medullary thyroid cancer (MTC).
|
24488334 |
2014 |